secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040608
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals to effect 1-for-10 reverse stock split effective April 1, 2024 to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.
- Effective at 4:30 p.m. ET on April 1, 2024; trading on split-adjusted basis begins April 2, 2024 under symbol NRXP.
- Fractional shares rounded up to nearest whole share; par value unchanged.
- Chairman cites upcoming clinical trial readouts, planned NDA filing, and dividend of HOPE Therapeutics shares.
- CUSIP changes to 629444209; stockholders need not exchange certificates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/0001104659-24-040608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/tm2410082d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer